ProbarE i Lund AB
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The site is evaluating innovative treatments aimed at reducing major cardiovascular events in patients with metabolic disorders, while also exploring therapies that protect heart health in broader populations.
- Type 2 Diabetes Mellitus
- Type 1 Diabetes Mellitus
Across 15 studies, ProbarE i Lund leverages a team of three investigators to advance cardiovascular safety and efficacy research.
Immune System Diseases
Research at this facility focuses on modulating immune activity to improve outcomes for patients with chronic inflammatory conditions, testing both novel biologics and established therapies.
- Moderate-to-Severe Plaque Psoriasis
- Birch Pollen-induced Allergic Rhinoconjunctivitis
The trials aim to demonstrate safety and longer‑term benefit for individuals living with immune‑driven skin and allergy disorders.
Nervous System Diseases
Investigations target acute neurological pain and mood disorders, seeking faster relief for migraines and more effective adjunctive options for depression.
- Acute Migraine
- Major Depressive Disorder
- Major Depressive Disorder with Anhedonia
- Major Depressive Disorder with Insomnia
By combining new agents with standard antidepressants, the studies aim to enhance symptom control for adults and adolescents.
Nutritional and Metabolic Diseases
The program evaluates therapies that preserve pancreatic function and improve glycemic control, addressing both early‑onset and adult diabetes.
- Type 1 Diabetes Mellitus
- Type 2 Diabetes Mellitus
Outcomes focus on beta‑cell preservation and cardiovascular risk reduction in newly diagnosed and established diabetes.
Respiratory Tract Diseases
Clinical work concentrates on reducing flare‑ups and improving lung function for patients with chronic obstructive pulmonary disease, using both inhaled combinations and systemic biologics.
- Chronic Obstructive Pulmonary Disease
- COPD with Frequent Exacerbations
The trials assess exacerbation rates, safety, and quality‑of‑life improvements for individuals with severe respiratory disease.
Skin and Connective Tissue Diseases
Studies aim to provide durable skin clearance and reduce systemic inflammation for patients with severe plaque psoriasis, evaluating long‑term tolerability of targeted agents.
- Moderate-to-Severe Plaque Psoriasis
Participants receive extended treatment to gauge sustained efficacy and safety over multiple months.
Immune System Phenomena
Research explores how manipulating immune pathways can alter disease trajectories, testing cytokine‑targeted biologics across inflammatory indications.
- Biologic therapies for inflammatory conditions
- Immune pathway inhibition in respiratory disease
The focus is on understanding mechanistic effects and translating them into clinical benefit.
Mental Disorders
The site conducts trials that add novel agents to existing antidepressant regimens, seeking to alleviate persistent depressive symptoms and prevent relapse.
- Major Depressive Disorder
- MDD with Moderate‑to‑Severe Anhedonia
- MDD with Insomnia Symptoms
Long‑term safety and efficacy are monitored to support improved mental health outcomes for adults.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 17 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1AstraZeneca AB2active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB5trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 188 other sites in Sweden
Therapeutic Area Benchmark — Sweden
Select a therapeutic area to compare against other sites in Sweden.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Sweden
Market Share
Country: Sweden
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in ProbarE i Lund AB
lock Showing 1 of 17 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP 363856 in the Treatment of Adults with Generalized Anxiety Disorder | Otsuka Pharmaceutical Development & Commercialization Inc. | Phase IV | Not Recruiting | Sep 2023 | Sep 2025 |
IMP list
lock Showing 1 of 17 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Aticaprant | 2 | Unknown | 2023-06-12 | 2024-11-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.